We observed reciprocal activation of FAK following treatment with avutometinib or encorafenib, and the loss of this negative regulation might, in part, elucidate the activation of FAK in cancer cells subsequent to MAPK pathway blockade. This evidence concerns the gene PTK2 and cancer.